The approval is a significant milestone for Marksans Pharma in broadening its oncology product line and fortifying its position in the UK pharmaceutical market. Earlier in October, the UK subsidiary received marketing authorisation for the Clonidine 100 microgram tablets and Clonidine Hydrochloride 25 microgram tablets.

See Full Page